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Background: Microvascular obstruction (MVO) at the acute phase of myocardial infarction (MI) is associated with
poor prognosis. We aimed to evaluate the correlation between plasma cardiac troponin I (cTnI) at the acute phase
of MI and extent of no-reflow, as assessed by 3-T cardiac magnetic resonance imaging (MRI). Secondly, we defined
a cut-off value for cTnI predictive of no-reflow.
Methods: 51 consecutive patients with no previous history of cardiovascular disease, presenting ST elevation MI
within <12 h. Infarct size and extent of no-reflow were evaluated by 3-T MRI at day 5. Extent of no-reflow at 15
minutes (MVO) was correlated with cTnI at admission, 6, 12, 24, 48 and 72 hours. At 6 months, MRI was performed
to evaluate the impact of MVO on LV remodeling.
Results: MVO was diagnosed in 29 patients (57%). Extent of MVO was significantly correlated to peak troponin, cTnI
(except admission values) and area under the curve. Using Receiver-operating characteristic (ROC) curve analysis, a
cut-off cTnI value >89 ng/mL at 12 h seemed to best predict presence of early MVO (sensitivity 63%, specificity
88%). At 6 months, MVO was associated with left ventricular (LV) remodeling, resulting in higher LV volumes.
Conclusion: There is a relationship between cTnI at the acute phase of AMI and extent of MVO as assessed by 3-T
cardiac MRI. A cut-off cTnI value of 89 ng/mL at 12 h seems to best predict presence of MVO, which contributes to
LV remodeling.
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In acute ST-segment-elevation myocardial infarction
(STEMI), primary percutaneous coronary intervention is
the treatment of choice to restore myocardial revas-
cularization and minimize ischemic damage to the myo-
cardium [1]. Several studies have demonstrated that
microvascular dysfunction after infarct-related artery re-
vascularization is associated with myocardial reperfusion
injury, resulting in greater infarct size [2-10], left ventricu-
lar impairment [3-5,7,11-17], recurrent MI [2-4,14], heart
failure [2-4,12,14] and higher mortality [2-5,12,14,18,19].* Correspondence: nicolas.meneveau@univ-fcomte.fr
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unless otherwise stated.In addition, microvascular dysfunction has a nega-
tive prognostic value, irrespective of infarct size [3].
Magnetic Resonance Imaging (MRI) is not systematically
performed in routine practice, and it would thus be useful
if there was a more accessible prognostic marker that
could identify patients with microvascular obstruction
(MVO). Cardiac troponin levels correlate well with in-
farct size [20] and are of prognostic value in the
short and long term [21].
The aim of our study was to evaluate the relationship
between plasma levels of cardiac troponin I (cTnI) and
microvascular obstruction (MVO) as assessed by mag-
netic resonance imaging (MRI) at day 5, and to define a
cut-off value for cTnI that predicts MVO.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Study population
This study was a prospective single-center study. Pa-
tients < 75 years old referred to our department for a first
ST elevation MI (STEMI) and admitted within 12 hours
of symptom onset were considered for inclusion. MI was
defined by the guidelines of the joint Task Force of the
European Society of Cardiology (ESC), the American
College of Cardiology (ACC), the American Heart
Association (AHA), and the World Heart Federation
(WHF) [1,22]. MI was confirmed by detection of elevated
cardiac biomarkers (at least one value above the 99th per-
centile of the upper reference limit (URL)), together with
evidence of myocardial ischemia (i.e., new ST-T changes
or new left bundle branch block, or development of
pathological Q waves in the ECG).
Exclusion criteria were: previous cardiovascular or pul-
monary diseases, cardiogenic shock and contraindication
for MRI.
The study protocol was approved by the local ethics
committee (Comité de Protection des Personnes Est II,
University Hospital Besancon, France) and informed con-
sent was obtained from all enrolled patients.Angiographic evaluation
All patients were referred to the catheterization labo-
ratory within the first 24 hours after admission for cor-
onary angiogram, and received medication according to
current guidelines [1].
The initial and post-procedural blood flow in the
infarct-related artery was graded according to the Throm-
bolysis in Myocardial Infarction (TIMI) grading system
[23]. A successful procedure was defined by a TIMI flow
grade = 3 and residual stenosis < 20%.Magnetic resonance imaging
All CE-MRI studies were conducted at 3.0 field strength
(Signa HD, General Electric Healthcare, Milwaukee, WI,
USA) and performed in the acute phase and repeated
at 6 months. Left ventricular function was assessed by
ECG-gated cine steady-state free precession (SSFP) breath-
hold sequences in the two-chamber and four-chamber
views as well as in the short cardiac axis from base to apex
(30 phases per cardiac cycle; repetition time 3.5 ms, echo
time 1.2 ms, flip angle 45°, typical voxel size 1.92 × 1.25 ×
8.0 mm).
Contrast-enhancement imaging was performed at 3
and 15 min with a breath-hold ECG-gated T1-weighted
sequence after the injection of a bolus of gadolinium
(Dota-Gd; Guerbet, Roissy, France) at a single dose of
0.1 mmol/kg (TE =MinFull/field of view 440 mm/TI =
optimised to obtain an optimal myocardial nulling/mat-
rix 256 × 224, interpolated 256 × 256/slice thickness =8 mm/gap = 1 mm). The number and position of slices
were the same as used for functional imaging.
Image analysis was performed in a blind fashion by
two operators using an off-line dedicated workstation
(General Electric Healthcare, Milwaukee, WI, USA). Left
ventricular (LV) ejection fraction (LVEF), end-diastolic
(LVEDVI) and end–systolic volume index (LVESVI) and
mass were calculated from SSFP short-axis views. MVO
was assessed on the initial CE-MRI performed during in-
hospital stay. Infarct size was assessed from the same ini-
tial CE-MRI and at 6 months follow-up. Infarct size and
MVO (if present) were manually traced from the contrast-
enhancement short-axis images [24]. Myocardial regions
was considered infarcted if the infarct size signal intensity
was >2 SDs above the remote myocardium. MVO was de-
fined as a dark zone within the infarcted segments, usually
located in the subendocardium. MVO and infarct size are
expressed as a percentage of LV mass assuming 1.05 g/ml
as the specific gravity of myocardium.
Enzyme measurement
Serum levels of troponin I (TnI), creatine kinase (CK)
and creatine kinase isoenzyme myocardial and brain
(CK-MB) were determined on admission, and 6, 12, 24,
and 48 hours after onset of MI. cTnI was measured
quantitatively using sandwich immunoassay (Dimension
RXL max, SIEMENS, Germany). The lower limit of de-
tection for this assay was 0.04 ng/ml. A value of cTnl
> 0.15 ng/ml was considered indicative of myocardial
necrosis for the purposes of clinical care. The peak level
was determined as the highest value.
Statistical analysis
Quantitative continuous variables are expressed as mean ±
standard deviation, and qualitative variables as number
and percent. The Student t test and Chi square or Fisher’s
exact tests were used for comparisons, as appropriate. We
calculated the relative change at 6 months from baseline in
LV end-diastolic volume index, LV end-systolic volume
index, and LV ejection fraction. The model used to take
initial infarct size into account was the calculation of rela-
tive change, normalized for baseline infarct size. The corre-
lations between serum enzyme levels and MVO at day 5
were assessed using the Spearman rank test. A receiver-
operating characteristic (ROC) curve was used to define
the threshold value of troponin levels predictive of MVO
at day 5. A p-value <0.05 was considered statistically sig-
nificant. All analyses were performed using SAS version
9.2 (SAS Institute, Cary, NC, USA).
Results
Patient characteristics
Between 2006 and 2008, 51 patients were enrolled in the
study. Mean age was 54 years; there were 9 women and
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study population are shown in Table 1. Eighteen patients
(35%) had anterior MI location. All patients underwent
coronary angiogram and angioplasty within the first 24
hours. Reperfusion therapy was initiated 5.3 ± 3.2 hours
after the onset of symptoms, by primary PCI in 37 pa-
tients (73%) and thrombolysis in 14 patients (27%). In
patients who underwent thrombolysis, rescue PCI was
performed in 6 patients (12%) and the remaining 8
underwent systematic PCI within the first 24 hours after
reperfusion.
Twenty-nine patients (57%) had MVO (MVOpos pa-
tients) diagnosed by MRI and 22 (43%) had no MVO
(MVOneg patients). MVOpos and MVOneg patients were
comparable as regards baseline characteristics.The per-
centage of patients with TIMI flow grade ≤2 before PCI
was significantly higher in the MVO pos group. After
PCI, the rate of TIMI flow grade 3 was comparable in
both groups (Figure 1).
During follow-up, there were 0 deaths, and 4 revascu-
larisations (1 for recurrent MI due to stent thrombosisTable 1 Baseline and angiographic characteristics
Al




Family history of CAD (%)
Current smoking
Hyperlipidemia (%)
Body mass index ≥30Kg/m2(%)
One vessel disease (%)
Multivessel disease (%)
Stenosis < 50% (%)
Anterior location (%)





Clopidogrel loading dose (300/600 mg)
GP IIb-IIIa inhibitors (%)
TnI peak (ng/mL) (range)
CK peak, U/L (range) 19
CK-MB peak, U/L (range) 1
Pts MVOneg = patients without microvascular obstruction; Pts MVOpos = patients with
coronary intervention; TnI = troponin I; CK = creatine kinase; CK-MB = creatine kinaseat 12 days and 3 on arteries other than the infarct-
related artery).
Magnetic resonance imaging
MRI was performed at 5.7 ± 2.7 days after symptom on-
set and at 6 ± 1 months follow-up. MRI was not per-
formed in 6 patients at 6 months due to patient refusal,
or intervention (PCI or CABG) during the follow-up
period.
At day 5, the extent of MVO was 7.3 ± 3.7%. Infarct
size was 23.5 ± 8.4% in MVOpos patients versus 12.7 ±
9.4% in MVOneg patients (p = 0.0001). There was a sig-
nificant correlation between the extent of MVO at day 5
and the infarct size at day 5 (r = 0.61, p < 0.0001). Simi-
larly, we observed a significant correlation between extent
of MVO and time to reperfusion (r = 0.43, p = 0.004).
At 6 months follow-up, a significant positive cor-
relation was observed among MVOpos patients between
MVO at day 5 and infarct size at 6 months (Figure 2). In
MVOpos patients, the relative change in LV end-diastolic
volume index (LVEDVI) and in LV end-systolic volumel patients Pts MVOneg Pts MVOpos P
N = 51 N = 22 (43%) N = 29 (57%)
3.6 ± 9.9 56 ± 10 52.6 ± 9.4 0.27
9 (18) 4 (19) 5 (17.5) 0.93
18 (35) 7 (32) 11(38) 0.65
11 (22) 5 (23) 6 (21) 0.86
15 (29) 7 (32) 8 (27) 0.74
42 (82) 18 (82) 24 (83) 0.93
21 (41) 9 (41) 12 (41) 0.97
9 (18) 3 (14) 6 (20.6) 0.51
28 (55) 13 (59) 15 (52) 0.60
16 (31) 7 (32) 9 (31) 0.95
7 (14) 2 (9) 5 (17) 0.40
18 (35) 9 (41) 9 (31) 0.46
5.3 ± 3.2 4.7 ± 2.9 5.9 ± 3.7 0.21
14 (27) 5 (23) 9 (31) 0.73
37 (73) 17 (77) 20 (69)
6 (12) 2 (9) 4 (14) 0.94
51 (100) 22 (100) 29 (100) 1
34/17 14/8 20/9 0.69
22 (43) 8 (36) 14(48) 0.39
81 ± 71 53.6 (13–225) 118.5 (22–585) 0.0006
85 ± 1522 1825 (63–9580) 2663 (160–9930) 0.006
24 ± 132 145.6 (9–940) 189.1 (9–760) 0.09
microvascular obstruction; CAD = coronary artery disease; PCI = percutaneous
isoenzyme myocardial and brain.
Figure 1 TIMI flow grade before and after percutaneous
coronary intervention. TIMI = thrombolysis in myocardial infarction;
PCI = percutaneous coronary intervention; MVOneg = patients without
microvascular obstruction; MVOpos = patients with
microvascular obstruction.
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patients (p = 0.002 for LVEDVI, p = 0.004 for LVESVI)
(Figure 3). There was no significant difference in relative
change in LV ejection fraction (LVEF).
Enzyme measurement
Peak troponin and peak CK were significantly higher in
MVOpos patients (respectively p = 0.0006 and p = 0.006)
(Table 1).
There was no significant difference in terms of peak
troponin values between patients with TIMI flow grade
3 and those with TIMI flow ≤2 after revascularisation
(peak troponin 75 ± 58 vs 83 ± 65, TIMI 3 vs ≤2 respect-
ively, p = 0.65).Figure 2 Relationship between MVO at Day 5 and infarct size
at 6 months. MVO =microvascular obstruction; MVOpos = patients
with microvascular obstruction.Correlation between the extent of MVO and troponin I
levels
The extent of MVO at day 5 was significantly correlated
with peak troponin (Figure 4) and troponin I levels at 6,
12, 24, 48 and 72 hours (Table 2). Infarct size was signifi-
cantly correlated with peak troponin (p < 0.0001) and the
different cTnI levels (p < 0.001), except cTnI at admission.
Relationship between the presence of MVO and troponin I
levels
Peak troponin and all cTnI levels except cTnI at admis-
sion were significant predictors of MVO (Table 3). The
Area under the curve (ROC) varied from 0.68 for tropo-
nin at 72 h to 0.766 for troponin at 12 h. Sensitivity
varied from 56% for troponin at 48 h to 74% for tropo-
nin at 6 h. Specificity ranged from 65% for troponin at
6 h and 72 h to 88% for troponin at 12 h, 48 h and the
AUC troponin. Using ROC curve analysis, a cTnI level
> 89 ng/ml at 12 hours was found to be the best cut-off
value to predict MVO with a sensitivity of 63% and a
specificity of 88% (p < 0.0002) (Figure 5).
Discussion
We aimed to find an accessible prognostic marker that
could identify patients with microvascular dysfunction
after reperfusion at the acute phase of myocardial infarc-
tion. Our data demonstrated that troponin levels (except
troponin at admission), and particularly peak troponin,
were correlated with the extent of MVO on MRI at day
5. A troponin I level > 89 ng/ml at 12 hours was found
to be the best cut-off value to predict MVO, with a sen-
sitivity of 63% and a specificity of 88%.
The phenomenon of no-reflow [25,26] or microvascu-
lar obstruction is due to microembolization of athero-
sclerotic debris or thrombotic material, intimal oedema,
tissue haemorrhage and/or leukocyte sticking [8,27], and
is diagnosed well by MRI [3,6,13,28]. In addition, besides
microvascular obstruction, intra-myocardial hemorrhage
and microvascular destruction have also been shown to
play an important role in this setting [29]. At the acute
phase of MI, the successful restoration of epicardial cor-
onary artery patency does not always lead to adequate
reperfusion at the microvascular level. In our study, al-
though 93 to 95% of the patients had a TIMI flow
grade =3 after PCI at 24 h, MVO was diagnosed by MRI
in 57% of cases at day 5. There was no significant dif-
ference in peak troponin between patients with TIMI
flow grade 3 and those with TIMI flow ≤2 after revascu-
larisation. Several studies have shown that microvascular
dysfunction after infarct-related artery revascularization
is associated with myocardial reperfusion injury, result-
ing in greater infarct size [2-10], left ventricular impair-
ment [3-5,7,11-17], recurrent MI [2-4,14], heart failure
[2-4,12,14] and higher mortality [2-5,12,14,18,19]. In
Figure 3 Relative change at 6 months from baseline in left ventricular end-diastolic volume index (LVEDVI) and left ventricular end-
systolic volume index (LVESVI) normalized for baseline infarct size. MVOneg = patients without microvascular obstruction; MVOpos = patients
with microvascular obstruction.
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crease by 75% at 1 month [18], 67% at 1 year [5] and
50% at 5 years [19]. In our study, MVO at day 5 was as-
sociated with LV remodelling at 6 months, as reflected
by significantly increased left ventricular volumes as-
sessed on MRI. These results are comparable to those of
Orn et al. [7] at 1 year, and those of Nijveldt et al. [13]
at 4 months, using the MRI technique.
This is strong evidence that both serial and single-
point measurements of troponin correlate well with in-
farct size [8,9,20]. In routine practice, plasma levels of
troponin I are used by the clinician to estimate the ex-
tent of necrosis. In our study, infarct size was signifi-
cantly correlated with peak troponin and with the serial
troponin I levels, except for troponin values at admis-
sion. To date, only 3 studies have investigated the rela-
tionship between MVO as assessed by MRI and serial
troponin measurements, and the optimal timing for a
single measurement. Our results confirm those of the
literature. In the study of Neizel et al. [8], 61 patients
with STEMI <24 h reperfused by fibrinolysis or PCI, un-
derwent MRI within 4 ± 1 days and serial troponin TFigure 4 Relationship between MVO and Peak troponin.
MVO =microvascular obstruction.measurements at admission and after 24, 48, 72 and 96
hours. They found that a troponin T level > 2.52 μg/l at
24 h was a predictor for MVO with a sensitivity of 100%
and a specificity of 80%. In this study, Neizel et al. used
troponin T levels, and no troponin measurements were
performed between admission and 24 h. Furthermore,
MVO was evaluated on earlier delayed-enhancement im-
aging after contrast injection. Younger and al [9] en-
rolled 93 patients who underwent MRI on average 3.7 ±
1.4 days after medical treatment for acute ST elevation
or non-ST elevation myocardial infarction. Serum tropo-
nin I concentrations were sampled at 12 h and 72 h only
after admission. They found a close relationship between
a single measurement of troponin I at 72 h and the ex-
tent of MVO. The early and complete reperfusion of the
infarct-related artery accelerates the appearance of car-
diac enzymes in the first hours after reperfusion therapy.
This wash-out phenomenon is characterized by a steeper
rise and an earlier peak after successful restoration of
anterograde coronary blood flow. These changes are more
pronounced after mechanical reperfusion, which was used
in our study, than after thrombolytic therapy [8]. There-
fore, the almost exclusive reliance on thrombolytic therapyTable 2 Correlation between the extent of MVO and
troponin I levels
MVO (N = 29)
r p
Troponin peak 0.51 0.01
AUC troponin 0.58 0.01
Troponin on admission 0.11 0.59
Troponin at 6H 0.57 0.01
Troponin at 12H 0.67 <0.0001
Troponin at 24H 0.46 0.02
Troponin at 48H 0.57 0.01
Troponin at 72H 0.42 0.04
MVO =microvascular obstruction; AUC = area under the curve; H = hours.
Table 3 Cut-off value of cTnI predictive of MVO
Cut-off value (ng/ml) Se (%) Sp (%) AUC ROC p
Troponin at H6 44.6 74 65 0.729 0.0025
Troponin at H12 89 63 88 0.766 0.0002
Troponin at H24 27.4 65 81 0.703 0.0116
Troponin at H48 16.35 56 88 0.724 0.0041
Troponin at H72 7.9 71 65 0.68 0.0308
Peak troponin 79.9 63 82 0.761 0.0003
AUC Troponin 275.3 59 88 0.726 0.0057
Se = sensitivity; Sp = specificity; AUC = area under the curve; ROC = receiver operating characteristic; H = hours.
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delayed troponin release observed. In study by Mayr and
al [10], MRI was performed in 118 patients within 8 days
after successful interventional reperfusion of STEMI. Car-
diac troponin T concentrations were measured at least 3
times during the first 24 h after admission, and subse-
quently on days 1, 2, 3 and 4. These authors demonstrated
that a peak troponin > 4.7 μg/l was predictive of MVO
with a sensitivity of 78% and a specificity of 83%.
One of the advantages of the present study is the large
number of repeat troponin measures, at relatively short
time intervals, which allowed more accurate determin-
ation of a threshold value that could predict MVO at the
acute phase of infarction.
It has previously been shown that a longer duration of
ischemia is associated with more pronounced impair-
ment of myocardial perfusion and consequently, infarct
size [30]. In our study, we observed a correlation be-
tween the extent of MVO and the time to reperfusion.Figure 5 Cut-off value of cTnI predictive of MVO. ROC curves
established for: AUC troponin (AUC ROC 0.726, 95% CI 0.56-0.86). Peak
troponin (AUCROC 0.757, 95% CI 0.59-0.88). Troponin at 12 hours
(AUCROC 0.763, 95% CI 0.6-0.88) cTnI = cardiac troponin I; MVO =
microvascular obstruction; ROC = receiver operating characteristic;
AUC = area under the curve.Thus, the relation between troponin and the presence of
MVO should be interpreted taking into account the time
to reperfusion, since restoration of TIMI flow grade 3 by
angioplasty does not necessarily guarantee the normaliza-
tion of myocardial perfusion [31].
Newton et al. previously studied MVO on MRI in the
context of non-ST elevation MI, and observed that MVO
was correlated with infarct size and troponin levels. Thus,
it would appear that the results observed in the context of
STEMI are also applicable in NSTEMI [32].
Study limitations
This is a single-center study, with a relatively small
population of highly selected patients. Nonetheless, the
selection of the population made it possible to independ-
ently analyse MVO as evaluated by MRI in the absence
of other cardiovascular comorbidities. Secondly, we did
not evaluate blush grade, which corresponds to the an-
giographic evaluation of microcirculation after revascu-
larisation. Our study focused on MVO at 5 days, which
is a different phenomenon, and shown to be an inde-
pendent prognostic factor in acute MI. These results
merit further confirmation in a larger, prospective study.
Thirdly, reperfusion strategy (primary PCI or thromboly-
sis) may possibly influence the occurrence of MVO. In
particular, it has been shown that rescue PCI is associ-
ated with an increased thrombotic risk in this setting.
However, in our study, only 6 (12%) patients underwent
rescue PCI. This likely did not impact on the relation
observed between MVO and peak troponin, as there was
no significant difference between groups (Table 1).
Fourthly, MRI could not be performed in 6 patients
(11.7%) at 6 months. However, this does not impact
the interpretation of the primary endpoint evaluated
at 5 days.
Conclusion
Our results suggest a correlation between plasma levels
of cardiac troponin I at the acute phase of AMI, and the
extent of MVO as assessed by 3-T cardiac magnetic reson-
ance imaging. The extent of MVO at 5 days post-STEMI
is correlated with infarct size, and negatively impacts on
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http://www.biomedcentral.com/1471-2261/14/57LV remodeling at 6 months. A cut-off value of 89 ng/mL
for cTnI at 12 hours seems to best predict the presence of
early MVO with high sensitivity and specificity. Troponin
measurement is an easily accessible prognostic marker
that could help identify patients with MVO and unfavor-
able prognosis.
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